Pembrolizumab Vibostolima

MK-7684A was Merck's attempt to extend the Keytruda franchise by welding pembrolizumab (anti-PD-1) to vibostolimab (anti-TIGIT) in a single fixed-dose vial. The KEYVIBE Phase 3 program across lung cancer indications, including KEYVIBE-008 in first-line extensive-stage small cell lung cancer (NCT05224141), was wound down in 2024 after multiple trials failed pre-specified futility criteria for overall survival [1][2]. The database still lists this node as phase3 because the schema has no 'discontinued' enum, but the commercial reality is that MK-7684A is dead and TIGIT as a checkpoint target is now one of the most expensively invalidated hypotheses in oncology [3][4].

MK-7684A was a novel co-formulation combining an approved antibody (pembrolizumab) with an investigational one (vibostolimab). It never received FDA breakthrough, fast track, or accelerated approval designation. KEYVIBE-008, the NCT05224141 study underlying this node, was a Phase 3 first-line extensive-stage SCLC trial against atezolizumab plus etoposide/platinum chemotherapy, the current standard of care [5]. Merck disclosed in 2024 that an independent data monitoring committee recommended stopping KEYVIBE-008 and the other KEYVIBE Phase 3 studies for futility on overall survival, and the company subsequently discontinued the program [1]. ClinicalTrials.gov still lists NCT05224141 as active-not-recruiting rather than terminated, which is why automated status fields read 'phase3' rather than 'discontinued.' There is no expected readout, no regulatory submission in motion, and no path forward for this specific molecule. Vibostolimab itself has no other active Phase 3 wrapper, and Merck's TIGIT narrative on earnings calls has quietly disappeared since the 2024 futility calls [1].

The idea was straightforward on paper. PD-1 is a brake on T cells: tumors engage it to shut off the immune attack, and Keytruda releases that brake. TIGIT is a second, parallel brake on a partly different set of immune cells - PD-1 is mainly engaged on exhausted effector T cells, while TIGIT is expressed on both effector T cells and regulatory T cells (Tregs) inside tumors and signals through a distinct downstream pathway [6]. The hypothesis across the whole class was that pressing both brake-releases together would wake up more T cells than hitting PD-1 alone, especially in tumors where single-agent PD-1 blockade is only modestly effective. The biology is real. TIGIT engagement does inhibit T-cell activation, and vibostolimab's Phase 1 showed signs that the drug reached and bound its target as intended [6]. The problem is translation. Across sponsors, dual PD-1 plus TIGIT blockade has repeatedly failed to beat PD-1 alone on hard endpoints in large randomized trials. Roche's tiragolumab missed in SKYSCRAPER-01 (NSCLC) and SKYSCRAPER-02 (SCLC), and now Merck's vibostolimab program followed with KEYVIBE futility calls in overlapping indications [3][4]. The leading candidate explanation is Fc engagement: the Fc tail of an antibody determines whether it recruits immune cells to kill whatever the antibody is bound to, and TIGIT antibodies across sponsors differ in whether they are designed to use that mechanism to deplete regulatory T cells. Whether that difference actually matters for efficacy remains unresolved, and no sponsor has yet shown a Phase 3 OS win that would settle it.

KEYVIBE-008 (NCT05224141) was a randomized Phase 3 study in first-line extensive-stage small cell lung cancer. Patients received either MK-7684A plus etoposide and platinum chemotherapy, or atezolizumab plus the same chemotherapy backbone, which is the current standard of care anchored by the IMpower133 regimen [5][7]. The primary endpoint was overall survival. Enrollment target was approximately 460 patients. The design itself was defensible: a head-to-head against an approved regimen in a disease where single-agent PD-L1 blockade adds only modest OS benefit and where the field badly needs something better than two or three months of median incremental survival. The failure mode was not design. It was that MK-7684A did not clear futility on OS versus the atezolizumab arm. Because KEYVIBE-008 was stopped at an interim analysis on the IDMC's futility recommendation, Merck did not disclose final OS hazard ratios or median survival figures - the data matured only to the point of crossing the pre-specified futility boundary. KEYVIBE-003 (NSCLC), -006 (first-line NSCLC), -007 (NSCLC), and -010 (adjuvant melanoma) hit similar outcomes in overlapping timeframes in 2024, with Merck disclosing the discontinuation decisions through press releases and subsequent 10-K disclosures [1][8]. The totality rather than any single trial sealed the program.

Our model estimates a 25% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

The primary risk already materialized: dual PD-1 plus TIGIT blockade did not improve overall survival over the standard chemo-immunotherapy backbone in multiple randomized Phase 3 settings [1][3][4]. That is a target-level failure, not a dosing or formulation issue, and it is the reason competitors have been pulling back from TIGIT. Secondary risks that remain relevant for interpretation: toxicity from the combination was manageable but added infusion reactions and increased immune-related adverse events over pembrolizumab alone [6]. Commercially, even a successful readout would have faced reimbursement pressure because adding a novel antibody to a Keytruda-based regimen raises cost without a clear value story absent large OS gains. Execution risk is now moot. The remaining risk for Merck as a company is portfolio concentration: Keytruda generated roughly $29.5 billion in 2024, approximately 46% of Merck's total 2024 revenues of about $63.6 billion (and roughly 51% of the pharmaceutical segment's $57.4 billion), and MK-7684A was one of the lead programs intended to extend the franchise beyond loss of exclusivity in 2028 [1]. The KEYVIBE failure removes a meaningful piece of that LOE defense and raises pressure on subcutaneous Keytruda, the LAG-3 combinations, and bolt-on M&A.

This is a closed chapter, not a signal to watch. MK-7684A should be re-coded as discontinued once the schema supports it, and the pos_score should not be interpreted as a live forecast. The useful thing to track from here is Merck's Keytruda loss-of-exclusivity defense: how fast subcutaneous pembrolizumab (Keytruda Qlex, FDA-approved in 2025, launching into the US in 2026) ramps and converts IV patients ahead of 2028 LOE, the LAG-3 and individualized neoantigen (V940/mRNA-4157 - a personalized cancer vaccine built from mutations unique to a patient's tumor) programs with Moderna, and any M&A moves to replace the roughly $25 to $35 billion revenue hole that opens after 2028 [10][11]. For the TIGIT class more broadly, the next real data points are the second-generation TIGIT antibodies. Domvanalimab's STAR-121 Phase 3 in first-line NSCLC (Arcus/Gilead/AstraZeneca) has an expected study completion of December 2027 [12]; belrestotug's RELATIVITY-121 Phase 3 program sits on a similar horizon. If either produces a positive OS read, reopen the TIGIT class thesis. We have not confirmed whether Merck is running exploratory biomarker analyses on banked KEYVIBE samples to rescue the hypothesis in a subset; absent a disclosed effort, assume the class is functionally invalidated for front-line lung cancer. Check back when a sponsor publishes a positive, biomarker-anchored Phase 3 TIGIT readout, or when Merck discloses its post-KEYVIBE immuno-oncology strategy on an earnings call.